Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Application of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as biomarkers in the clinical management of multiple sclerosis (NeuroFilMS): a protocol for an observational cohort study.

BMJ open·2026
Same author

Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache.

European journal of neurology·2026
Same author

Propionic acid and neurofilament light chain in multiple sclerosis.

Brain : a journal of neurology·2026
Same author

Evolution of blood biomarkers reflective of brain tissue damage and inflammation in the perioperative course of intracerebral haemorrhage evacuation in a phase II proof-of-concept trial.

BMJ open·2026

Related Experiment Video

Updated: May 5, 2026

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.4K

Advanced Quantitative MRI Unveils Microstructural Thalamic Changes Reflecting Disease Progression in Multiple

Alessandro Cagol1, Mario Ocampo-Pineda1, Po-Jui Lu1

  • 1From the Translational Imaging in Neurology (ThINk) Basel (A.C., M.O.-P., P.-J.L., M.W., M.B., L.M.-G., X.C., L.K., C.G.), Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel; Department of Neurology (A.C., M.O.-P., P.-J.L., M.W., M.B., L.M.-G., X.C., J.K., L.K., C.G.), University Hospital Basel; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) (A.C., M.O.-P., P.-J.L., M.W., M.B., L.M.-G., X.C., J.K., L.K., C.G.), University Hospital Basel and University of Basel, Switzerland; Dipartimento di Scienze della Salute, (A.C., M.P.S.), Università degli Studi di Genova, Italy; Division of Radiological Physics (M.W.), Department of Radiology, University Hospital Basel; Laboratory for Research in Neuroimaging (A.L.), Department of Clinical Neuroscience, Lausanne University Hospital and University of Lausanne; Neuropsychology and Behavioral Neurology Unit (P.C.), Division of Cognitive and Molecular Neuroscience, University of Basel, Switzerland; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy.

Neurology(R) Neuroimmunology & Neuroinflammation
|September 13, 2024
PubMed
Summary

Advanced MRI reveals significant thalamic damage in multiple sclerosis (MS) patients, linked to disease progression. Quantitative MRI biomarkers show potential for guiding future MS treatments.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.4K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

8.9K

Related Experiment Videos

Last Updated: May 5, 2026

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.4K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.4K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

8.9K

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomarkers

Background:

  • Thalamic atrophy is common in multiple sclerosis (MS).
  • Mechanisms of thalamic volume loss and its relation to disease progression are poorly understood.
  • In vivo characterization of thalamic microstructure in MS is needed.

Purpose of the Study:

  • To comprehensively characterize in vivo pathologic changes within thalamic microstructure in patients with MS (PwMS) using advanced multiparametric quantitative MRI (qMRI).
  • To compare thalamic alterations between PwMS and healthy controls (HCs) and among MS disease phenotypes.
  • To investigate the relationship between thalamic damage and clinical/MRI measures of disease severity.

Main Methods:

  • Quantitative T1, magnetization transfer saturation, multishell diffusion, and quantitative susceptibility mapping (QSM) were used to assess thalamic microstructural integrity.
  • Cross-sectional and longitudinal data were collected from 183 PwMS and 105 HCs, with a 2-year follow-up for 127 PwMS and 73 HCs.
  • PwMS included relapsing-remitting MS (RRMS) and progressive MS (PMS) phenotypes.

Main Results:

  • PwMS showed significant thalamic alterations including demyelination and disrupted iron homeostasis, affecting normal-appearing tissue.
  • Longitudinal analysis revealed accelerated myelin loss and neurodegeneration in PwMS.
  • Progressive MS (PMS) demonstrated significantly accelerated thalamic degeneration compared to RRMS.
  • Thalamic qMRI alterations correlated with clinical, cognitive, and conventional MRI measures of disease burden.
  • Disability progression was associated with accelerated thalamic degeneration, with qMRI metrics predicting disability.

Conclusions:

  • Thalamic damage in MS is extensive and clinically relevant, strongly linked to disease progression.
  • Advanced qMRI biomarkers offer potential for monitoring and guiding interventions for thalamic neurodegeneration in MS.